Intermittent Theta-Burst Stimulation (iTBS) as an add-on to Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Post-traumatic Stress Disorder (PTSD)

Post-traumatic stress disorder (PTSD) is a disabling psychiatric condition characterized by intrusive traumatic memories, avoidance behaviors, negative alterations in cognition and mood, and persistent hyperarousal. Although trauma-focused psychotherapies such as Eye Movement Desensitization and Reprocessing (EMDR) are recommended as first-line treatments, a substantial proportion of patients continue to meet diagnostic criteria for PTSD despite receiving evidence-based psychotherapy.

Intermittent theta-burst stimulation (iTBS), a brief form of repetitive transcranial magnetic stimulation (rTMS), has demonstrated preliminary efficacy in reducing PTSD symptoms and offers practical advantages due to its short treatment duration.

The present study aims to investigate whether iTBS can be feasibly integrated as an adjunctive intervention for patients who do not respond sufficiently to EMDR therapy alone. This is an investigator-initiated, open-label feasibility study conducted within psychiatric services in the Central Denmark Region.

Eligible adults aged 18 to 70 years with a diagnosis of PTSD, who are referred for EMDR treatment, will be enrolled. Participants will receive standardized EMDR therapy consisting of sixteen weekly 90-minute sessions. Following completion of seven EMDR sessions, treatment response will be evaluated using the Clinical Global Impression-Improvement (CGI-I) scale. Participants rated as having insufficient improvement (CGI-I score ≥3) will be offered add-on iTBS.

The iTBS intervention will be delivered to the right DLPFC using a MagPro R30 stimulator and Cool-B70 coil. Treatment will consist of one daily iTBS session administered five days per week over four weeks for a total of 20 sessions. Participants will continue weekly EMDR therapy throughout the iTBS phase and subsequent follow-up period.

The primary objectives are to evaluate the safety, tolerability, and feasibility of the combined EMDR+iTBS intervention. Feasibility outcomes include treatment adherence, treatment completion rates, and dropout rates. Secondary outcomes include adverse events and changes in PTSD symptom severity measured using clinician-rated and self-reported instruments.

• Symptom trajectories [Срок оценки: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)]
• Symptom trajectories [Срок оценки: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)]
• Symptom trajectories [Срок оценки: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)]
• Symptom trajectories [Срок оценки: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)]
• Adverse event rates [Срок оценки: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)]
• Adverse event rates [Срок оценки: Time Frame: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)]
• Changes in mental well-being [Срок оценки: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)]